VICO was founded in Q4 2019 by the highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.
Become a recognized leader bringing innovative oligonucleotide based RNA modulating therapeutics to patients suffering from rare CNS disorders.
We foster positive and collaborative relationships with all stakeholders, including patients, academics, physicians and our employees, essential for the development of new therapies for rare CNS disorders.
It is our mission to advance these therapies and our team is committed to realize the full potential of our pipeline and technologies to the benefit of patients.
Our programs are driven by a highly competent and experienced team consisting of molecular biologists, chemists and drug development experts with over a decade of experience in bringing novel therapies into the clinic and to the market.
Chief Executive Officer
Judith van Deutekom
Managing Director & Chief Scientific Officer
Chief Development Officer
Chief Operating Officer
Chief Medical Officer